Anteris Tech's DurAVR THV heart valve was implanted successfully in a procedure. Picture Getty
Health & Biotech
Anteris Technologies (ASX:AVR) said that its DurAVR THV device – the world’s only balloon-expandable, single-piece transcatheter aortic valve – has been implanted in a second successful Valve-in-Valve (ViV) procedure in Canada.
A ViV procedure is required for patients with a life-threatening situation where their current bioprosthetic aortic valve is failing due to calcification or structural deterioration, and where a new heart valve must be implanted inside the failing valve.
In the latest procedure, DurAVR THV was implanted in a 79-year-old female who was previously implanted with a Trifecta surgical valve that had severely degenerated, causing debilitating symptoms.
Anteris says the results after DurAVR THV was implanted were ‘phenomenal’, with a mean pressure gradient of 7mmHg, restoring near-normal physiology. The patient was safely discharged less than 24 hours after the procedure.
“Today’s case demonstrated what we saw in pre-clinical testing; that DurAVR has the potential to offer superior gradients for ViV patients,” said Dr Janar Sathananthan, an cardiologist at Vancouver General Hospital where the procedure was performed.
Currently, available commercial products can leave patients with a high risk of remaining in a diseased state post-procedure, with unsatisfactory high gradients.
“This is a great result in a small surgical valve at high risk for elevated gradients,” added Dr. Sathananthan.
Imugene (ASX:IMU) says its Phase 1 MAST (metastatic advanced solid tumours) trial evaluating its cancer-killing virus CF33- hNIS (VAXINIA) has cleared the cohort 3 intratumoral arm of the study.
This allows Imugene to commence recruitment for cohort 4 of the monotherapy dose escalation, where VAXINIA will be administered in three-to-six patients.
This Phase 1 trial commenced by delivering a low dose of VAXINIA to patients with metastatic or advanced solid tumours who have had at least two prior lines of standard of care treatment.
“We continue to rapidly advance our monotherapy dose while the combination study continues its positive progress,” said Imugene CEO, Leslie Chong.
Meanwhile, MGC Pharma (ASX:MXC) has announced positive results from the recently completed Pre-clinical Chronic Toxicology Evaluation of 14 days oral dose of CimetrA.
The study demonstrated full chronic safety and toxicology profile of CimetrA in large animals, and the drug was found to be totally safe.
Histopathological analysis of the full organs spectrum showed that all tissues of all the animals were normal and unaffected.
“We are delighted with the positive clinical trial results for CimetrA, which now paves the way for our IND submission to the FDA next year,” said MGC Pharma CEO, Roby Zomer.
Previous studies have shown that CimetrA’s mechanism of action as an anti-inflammatory and immuno-modulatory agent is effective in the prevention of severe viral inflammation such as Covid-19.
At Stockhead we tell it like it is. While MGC Pharmaceutical is a Stockhead advertiser, it did not sponsor this article.
Health & Biotech
Health & Biotech
Health & Biotech
Mining
Mining
Mining
Get the latest Stockhead news delivered free to your inbox.
